Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
about
B-cell-targeted therapies in relapsing forms of MS.Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications.Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
P2860
Q42631407-9396D4B6-149D-4890-BD4D-85DBE6A78B43Q46059217-689FE0F1-61F8-4118-814A-4CAD84123BF0Q47102132-9272EE2E-3344-421A-A29A-E138DC33E987Q47657261-3D2BFF68-DF07-4A23-B84E-1F8884DA4453Q48098182-2A1B03C5-26A8-4FFE-BD36-2F55069797DFQ48278134-6665039E-0EAB-49D5-B89F-069B6B4401FEQ58573155-10C0C70A-19AA-4C6A-AEC0-7F4BE3B23D30
P2860
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@ast
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@en
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@nl
type
label
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@ast
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@en
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@nl
prefLabel
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@ast
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@en
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@nl
P2093
P2860
P356
P1476
Inebilizumab, a B Cell-Depleti ...... ights from Preclinical Studies
@en
P2093
Nancy Monson
Ronald Herbst
Sandra Gallagher
P2860
P356
10.3390/JCM5120107
P407
P577
2016-11-24T00:00:00Z